Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025

Dow Jones07-10

Prime Medicine, Inc. (PRME) is currently at $3.64, down $0.59 or 13.83%

 

--Would be lowest close since June 26, 2026, when it closed at $3.43

--On pace for largest percent decrease since May 19, 2025, when it fell 16.04%

--Currently down two consecutive days; down 21.1% over this period

--Worst two day stretch since the two days ending May 20, 2025, when it fell 26.1%

--Down 5.81% this week; worst weekly performance since the week ending June 12, 2026, when it fell 9.31%

--Down 1.22% month-to-date

--Up 5.04% year-to-date

--Down 82.74% from its all-time closing high of $21.12 on Nov. 11, 2022

--Down 16.21% from 52 weeks ago (July 11, 2025), when it closed at $4.35

--Down 45.35% from its 52-week closing high of $6.67 on Oct. 2, 2025

--Up 35% from its 52-week closing low of $2.70 on May 19, 2026

--Traded as low as $3.62; lowest intraday level since July 1, 2026, when it hit $3.61

--Down 14.42% at today's intraday low; largest intraday percent decrease since June 5, 2026, when it fell as much as 15.27%

 

All data as of 11:49:13 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

July 10, 2026 11:52 ET (15:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment